Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARN-509 in Advanced Castration-Resistant Prostate Cancer
NCT01171898Phase 2Completed
- Sponsor
- Aragon Pharmaceuticals
- Start
- Jul 2010
- Primary completion
- Aug 2012
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of apalutamide in prostate cancer (PCa) (4 arms), sponsored by Aragon Pharmaceuticals. Primary endpoint: Percentage of Participants With >= 50% Reduction in Prostate-Specific Antigen at 12 weeks. Started Jul 2010; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01171898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171898.